GEN Exclusives

More »

GEN News Highlights

More »
Aug 7, 2008

Miraculins Gains Rights to Mount Sinai Biomarkers for Preeclampsia

  • Miraculins reports that it is licensing a portfolio of biomarkers from Mount Sinai Hospital for use in diagnostic assays for the early detection of preeclampsia.

    The signing of the term sheet between these organizations includes the biomarker endoglin, a cell surface glycoprotein. Recent studies have shown that it increases in week 17–20 of gestation and that it also plays a role in identifying the highest risk patients.

     



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?